Citigroup Raises ResMed Price Target to $270 From $240
Citigroup lifted its price target on ResMed shares to $270 from $240, according to Dow Jones Newswires citing Benzinga data.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Citigroup raised its price target on ResMed, a maker of medical equipment, to $270 per share from $240. The rating action was recorded in Benzinga's analyst data, and Dow Jones Newswires reported the change.
why it matters
A price target change from a single brokerage analyst mainly concerns the company itself and rarely moves the broader market. For ResMed investors, it is a signal of how one large bank now values the stock.
tags
instruments
sources
- ResMed Price Target Raised to $270.00/Share From $240.00 by Citigroup — Dow Jones Newswires, 30 October 2026 at 20:47 UTC
- Cleveland-Cliffs Price Target Raised to $14.00/Share From $12.00 by Citigroup — Dow Jones Newswires, 30 October 2026 at 21:11 UTC
- Saia Price Target Raised to $434.00/Share From $429.00 by Citigroup — Dow Jones Newswires, 30 October 2026 at 21:09 UTC
- Teradata Price Target Raised to $40.00/Share From $36.00 by Citigroup — Dow Jones Newswires, 30 October 2026 at 21:29 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗